This application is a §371 national phase of International application PCT/AU2007/000726 filed May 25, 2007, which claims foreign priority to Australian Patent Application no. 2006-902907 filed May 30, 2006.
The present invention relates to a method and apparatus for determining frequencies for use in performing impedance measurements on a subject, as well as to a method and apparatus for performing impedance measurements.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that the prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Bioelectrical Impedance Analysis (BIA) measures the impedance to flow of an alternating electrical current passed through biological tissue. Such impedance measurements are typically performed at a number of different frequencies, allowing a subject's impedance response to be modelled, using a mathematic relationship, such as the Cole model. This in turn enables the estimation of various parameters, which can in turn be used to derive information regarding a subject's health.
However, the frequencies used are typically selected randomly, or based on the ability of the measuring device used to perform the measurements. Consequently the effectiveness and accuracy of the measurements varies greatly.
In a first broad form the present invention provides a method of determining frequencies for use in performing impedance measurements, the method including:
Typically the method includes, determining the estimates for the parameter values at least in part using a model of the subject's impedance response.
Typically the method includes:
Typically the method of determining the residual variance model includes using an expectation maximization algorithm.
Typically the method includes determining a range of parameter values representing the impedance response of a number of subjects.
Typically the method includes:
Typically the model includes at least one of:
Typically the model includes determining the design by optimising the determinant of the Fisher information matrix.
Typically the design is a D-optimal design.
Typically the method includes determining a design space to take into account practical limitations.
Typically the method includes, modifying the design by at least one of:
Typically the method is performed at least in part using a processing system.
Typically the method includes, in the processing system:
Typically the method includes, in the processing system:
Typically the method includes, in the processing system:
Typically the method includes, in the processing system, optimising a determinant of the Fisher information matrix for the model.
Typically the method includes, in the processing system:
Typically the method includes, in the processing system, determining frequencies for use in impedance measurements within the range:
Typically the frequencies are within the ranges:
Typically the frequencies are:
Typically the frequencies are:
In a second broad form the present invention provides apparatus for determining frequencies for use in performing impedance measurements, the apparatus including, a processing system for:
Typically the apparatus is for performing the first broad form of the invention.
In a third broad form the present invention provides a method of measuring the impedance of a subject the method including, the method including, in a measuring device:
Typically a restricted range of frequencies can be defined by the ranges:
Typically the frequencies are approximately:
Typically the frequencies are:
Typically the method includes determining one or more impedance parameter values based on the plurality of measured impedance values.
In a fourth broad form the present invention provides apparatus for measuring the impedance of a subject the apparatus including a measuring device for:
Typically the measuring device includes:
Typically the apparatus is for performing the method of the third broad form of the invention.
Examples of the present invention will now be described with reference to the accompanying drawings, in which:—
An example of a process for determining frequencies at which impedance measurements may be made will now be described with reference to
At step 100 parameter values are determined representing the impedance response of one or more subjects. The parameter values may be determined in any one of a number of manners, such by modelling impedance data collected from a number of subjects from a prior study, as will be described in more detail below.
At step 110 the parameter values are used to determine an optimal design for studying the impedance response of the one or more subjects. This can be achieved, for example, by optimising designs representing frequencies that may be used in performing impedance measurements according to optimality criteria.
At step 120 the optimal designs may optionally be modified to take into account practical effects, such as the variants of subjects within a population to impedance measurement.
At step 130 the optimal designs are used to determine frequencies that may be used for performing impedance measurements.
The process may be performed manually, but typically requires advanced computation and therefore typically requires the use of a processing system.
An example processing system is shown in
In use the processing system 200 executes applications software stored in the memory 211, to allow parts of the process to be performed, as will be described in more detail below. It will be appreciated from this that the processing system 200 may be any suitable form of processing system 200, such as a personal computer, desktop, laptop, super computer, Sparc station, or the like.
An example of the process will now be described in more detail with respect to
In this example, at step 300 impedance data is collected from a sample population of subjects. The data is collected using a suitable measuring device that applies alternating electrical signals to a subject, and measures the electrical response of the subject. This is typically achieved by applying alternating currents to the subject at a number of different frequencies, and then measures voltage signals across the subject, to allow the impedance to be determined at each frequency. An example measuring device will be described in more detail below.
The impedance response of the subject can be modelled using a suitable model, such the Cole model, which is based on an equivalent circuit that effectively models the electrical behaviour of biological tissue, an example of which is shown in
In this example, the equivalent circuit includes two branches representing current flow through extracellular fluid and intracellular fluid. The extracellular component of biological impedance is represented by a resistance Re, whilst the intracellular component is represented by a resistance Ri and a capacitance C.
Accordingly, the impedance of the equivalent circuit of
However, as an alternative to the equivalent circuit described above, an alternative equivalent circuit incorporating a Fricke constant phase element (CPE) can be used, as will be understood by persons skilled in the art.
In any event, the equation (A) can be modified to include an exponent α to account for the distribution of time constants observed in biological tissues (or systems), as follows:
In this equation, R1, Re, C and α are parameters in the model, Z is the predicted impedance, j=√{square root over (−1)} and f is the frequency of the current passed through the body. R1 and Re are the resistances due to the intracellular and extracellular fluids in the body, respectively.
However, this is a theoretical model and in practice a subject's response will vary. Accordingly, at step 310 a residual variance model is selected to allow variations from the predicted response to be taken into account. The residual variance model may be selected in any one of ways as will be described in more detail below.
At step 320, parameter estimates are determined that represent the measured responses of the subjects. The initial parameters are parameters which when inserted into the models provide an estimate of the response of the sample population.
It will be appreciated that as different subjects within the sample population will have a range of different responses to impedance measurements. Accordingly, it is typical to model the range of responses across the sample population to allow the mean and variability of the parameters between subjects to be determined. This is effectively used to define a range of parameter values representing a parameter space.
At step 330, a number of Cole models are constructed across the parameter space, using the range of parameter values. This effectively models the range of different impedance responses of the subjects within the population.
At step 340 a Fisher information matrix is determined for the residual and Cole models. This can be achieved in any one of a number of ways, but typically involves using suitable applications software, such as the software package POPT by S. B. Duffull, implemented by the processing system 200.
At step 350, the product determinant of the Fisher information matrices is optimised. Again, this may be achieved in any one of a number of manners, such as by using a simulated annealing approach to find maxima for the expression. This provides an optimised design which represents the theoretical preferred frequencies at which impedance measurements may be made.
However, certain frequency measurements may not be practically achievable, or desirable. Thus, for example, theory may predict that the application of an electrical signal 0 kHz frequency will result in an improved subject response and hence improved impedance measurements. However, as the application of such a frequency is not practical, such a frequency is usually excluded. Similarly, high frequency measurements whilst theoretically advantageous, can be difficult to measure from a practical point of view, thereby further limiting the range of available frequencies. Accordingly, at step 360, a design space is selected that can be used to exclude such impractical frequencies.
At step 370 the optimal design can be used to determine preferred practical frequencies at which impedance measurements may be performed, together with an indication of the relative efficiency of the measurement procedure.
Accordingly, the above-described process operates by utilising impedance measurements for a sample population to determine optimal design, which can in turn be used to determine preferred frequencies for performing impedance measurements.
In one example, described in more detail in the specific example below, the process is used to determine that in general at least four frequencies should be used for performing impedance measurements. This can also be used to determine preferred frequency ranges for the four frequencies.
In one example, the preferred frequency ranges are as follows:
Limiting the design space based on practical constraints can lead to more specific frequency ranges as follows:
Even more preferably, the range of frequencies can be further limited to specific values as follows:
These are based on theoretical preferred frequencies calculated to be as follows:
Determination of the frequencies allows an impedance measuring device to be provided, which is adapted to utilise the preferred frequencies, as shown for example in
In this example the impedance measuring device typically includes a processing system 1 coupled to a current source 11 and a voltage sensor 12. The current source 11 is coupled via electrodes 13, 14 to a subject S with the voltage sensor being coupled to the subject S via electrodes 15, 16.
In use the processing system 1 causes the current source 11 to apply alternating current signals to the subject S via the electrodes 13, 14, at each of the preferred frequencies determined using the above described process. The response of subject S is then measured via the electrodes 15, 16 using the voltage sensor 12. The processing system 1 can then use details of the applied current and the measured voltage signals to determine an impedance value at each of the preferred frequencies.
By utilising the four measured frequencies, this allows parameters of the Cole model to be determined, such as the subject's impedance at a characteristic frequency Zc, as well as values for the intracellular and extracellular impedance. This in turn allows information such as indicators of the subject's of intracellular or extracellular fluid, or the ratio there between, to be determined.
A specific example of the above process will now be described in more detail.
In this example, the Cole equation described in Cole, K S (1940) Permeability and impermeability of cell membranes for ions Cold Spring Harbor Symposia on Quantitative Biology 8 110-122, is used to model bioimpedance. The model includes nonlinear parameters, which are known to vary between individuals. Accordingly the process uses the theory of experimental design to find the frequencies at which measurements of bioimpedance are optimally made. This can also be used to determine how many frequencies are needed in each patient in order to obtain good estimates of the parameters.
Experimental Design
Much of experimental design focuses on parameter estimation. A design is optimized, that is, the best choice of covariate settings and experimental effort is chosen, through assessment of an optimality criterion. Criteria considered in this paper are D-optimality and product design optimality, which are typically used to gain good parameter estimates for one or more models. Such criteria are based on the expected Fisher information matrix described in more detail below.
A Design ξ is defined by:
Use of the experimental effort factor is optional and included in this design for the purpose of example only and the following discussion will focus in examples in which the experimental effort is not taken into account, in which case the preferred Design ξ is defined by:
If xiεχ, then the design space can be written as
Fisher Information Matrix
For a model with response vector y=(y1, . . . , yn), dependent upon parameters θ and a design ξ, the expected Fisher information matrix can be defined as:
where l(θ; y) is the log-likelihood.
The Cramer-Rao lower bound described in H. Cramer “Mathematical methods of statistics.” Princeton, N.J.: Princeton University Press, pages 474-477, 1946, states that the variance-covariance matrix of any unbiased estimator of θ is bounded below by M−1 (θ,ξ). Thus, for given a design ξ, the expected Fisher information indicates how well to estimate the parameters in the model.
D-Optimality
A design ξ is D-optimal if it maximizes the determinant of the expected fisher information matrix. That is, arg maxξ|M(θ,ξ)|. This design will minimize |M−1(θ,ξ) which, minimizes the variance-covariance of {circumflex over (θ)}. Such D-optimal designs, therefore, in general provide good estimates of parameters since they minimise the ellipsoidal confidence regions around an estimate.
When comparing a designs ability to estimate model parameters, its D-efficiency is considered. The D-efficiency of the design ξ compared to the D-optimal design ξ* for a particular model is:
where pi is the number of parameters in the model.
A D-efficiency of 0.5 for ξ compared with ξ* means that twice as many samples need to be taken using ξ in order to obtain as accurate parameter estimates as given by ξ*.
Product Design Optimality
Product design is found when trying to obtain efficient parameter estimates for more than one model. Here the product of the determinants, scaled by the number of parameters, of each model is maximized giving a design ξ*D
where M1(θ1, ξ) is the expected Fisher information matrix for model 1 with parameters θ1 and p1 is the number of model parameters. Similarly for model 2.
Nonlinear Regression
A nonlinear model is specified by two main parts; a function expressing the predicted response and residual response variance structure. This, for the jth observation, can be written as follows:
yj=f(xj,θ)+εj (4)
where:
When modelling nonlinear data it is assumed that:
Often in practical applications, some of these assumptions do not hold. Accordingly, some generalizations or relaxations of this framework can be used so that the theory of nonlinear regression can be applied in these areas.
One relaxation is a generalization of the assumption of constant variance. Such a relaxation will allow flexibility in specifying intra-individual variance. This involves specifying a variance function h which can depend upon the predicted response E[yj], covariates xj and/or additional parameters δ. The model is then specified by:
E└yj┘=f(xj,θ)
Var[yj]=σ2h2(μj,xj,δ)
μi=f(xj,θ)
Such a specification generalizes assumption (iii) and allows for heteroscedasticity in the model.
The above defines a fixed effects model. However, to take into account variations between individuals, mixed effects models are typically used.
Fixed Effects Models
For a single individual, a fixed effects model (of the form yi=f(xi,θ)+εi) is considered. The expected fisher information matrix is defined as follows:
and W is a diagonalized n×1 vector of weights and
is a row vector of derivatives of the model with respect to the ith parameter evaluated at the covariates in ξ.
Mixed Effects Models
Mixed effects models allow for the analysis of individual data by incorporating fixed and random effects into a model. This gives two sources of variation; residuals within individuals and variation between individuals. Accordingly, the models have two types of coefficients; population-average and individual specific. One of the main applications of this theory is to repeated measures data.
It is known that where yi is a ni-vector of observations for the i-th individual, where i=1, . . . , N, and let the model be described by F(θi,ξi). Then:
yi=f(θi,ξi)+εi(s+tf(θi,ξi))
where ξi=(xi1, . . . , xin
Here ε is normally distributed with zero mean and a diagonal variance matrix characterized by parameters s and t so that s relates to the additive error component while t relates to the multiplicative error component.
Where θi is defined by β+bi, β is the vector of fixed effects and b is the vector of random effects for individual i. Here bi is normally distributed with mean zero and variance Ω.
The covariates for individual i is denoted by the vector xi, and θi is defined by g(β,bi,xi), where g is a known function. Ψ is an estimate of a vector of all population parameters, let γ be the vector of all variance terms. Then, Ψ′=[β′,γ′]
The Fisher information matrix for a population design
where Ξ={ξ1, . . . , ξN} and ξi is the ith individual design.
The Fisher information matrix for given values of x is given by:
where l(θ; y) is the log-likelihood of observations y for the population parameters θ. Due to the nonlinearity of f with respect to θ, there is no analytical expression for l(θ; y). That is, in general, for say N individuals where Y is a matrix of responses for the whole population and yi is the vector of responses for the ith individual, the likelihood can be expressed as:
Given the nonlinearity of bi in f, this integral is generally intractable. One solution for this integral is to approximate the nonlinear function with a first order Taylor expansion around the expected values of the random effects. The model is therefore:
Then the log-likelihood l is approximated by:
where E and V are the marginal expectation and variance of y given by:
Then the Fisher information matrix can be expressed as:
Thus, the approximate expected information matrix for a nonlinear mixed effects model is formed. This can now be used in a variety of optimality criteria to form designs with desired properties.
Bioelectrical Impedance Study
The application of these techniques to Bioelectrical impedance analysis (BIA), as modeled using the Cole equation, will now be explained. In particular D-optimal designs are derived based on different assumptions about the interaction between frequency and impedance and also the practical limitations of such a study.
This is achieved by obtaining initial parameter estimates by modeling data on individuals, using these initial estimates to form D-optimal designs and then extending these D-optimal designs so that they perform well in practice.
Optimal Designs for Studying Bioimpedance
In this example the Fisher information matrices are determined using the software package POPT written by S. B. Duffull. The search routine uses an adapted version of a simulated annealing algorithm for continuous variables. Together these techniques provide a means of finding D-optimal designs for nonlinear mixed and fixed effects models across a continuous search space.
Modeling the Data
For the Cole equation, initial parameter estimates were found by modeling paired frequency and bioimpedance data on 61 subjects. Whole-body, wrist to ankle, multifrequency bioimpedance data were recorded over the frequency range 5 to 1024 kHz using an Impedimed-SEAC SFB3 tetra-polar impedance instrument.
Modelling was performed using the software package MONOLIX, which is a MATLAB based package that uses stochastic approximation to the expectation maximization (SAEM) algorithm, in parametric maximum likelihood estimation for nonlinear mixed effects models.
The Expectation-Maximization (EM) algorithm is an iterative procedure used for likelihood function maximization given incomplete data sets formed from observable and non observable data. The E-step in this algorithm cannot be performed in closed formed due to the nonlinearity in f of the random effects, as described above.
The SAEM algorithm replaces this step with a stochastic procedure. Thus, the usual EM algorithm computes, at the kth iteration, the conditional expectation of the log-likelihood giving Qk(Ψ)=E[log p(y,bi;Ψ)|y,Ψk-1)], where p(y,bi;Ψ) is the likelihood of (y,bi).
The SAEM replaces this step by drawing bi(k) from the conditional distribution p(.|y;Ψk) and updates Qk(Ψ) as follows:
Qk(Ψ)=Qk-1(Ψ)+δk(log p(y,bi(k);Ψ)−Qk-1(Ψ))
To fit a nonlinear model to data, initial parameter estimates are also needed. For this model, initial estimates of fixed effects were taken from previous studies, and estimates of variance were found by what is called a ‘Standard Two Stage Approach’. This involves estimating fixed effects for all data specific to each individual. Then, the variance of these estimates is calculated and used as an estimate for Ω.
The first stage of the modeling process was to find a suitable residual variance model such that the residuals are normally distributed around zero so that tests, such as the likelihood ratio test, are valid. Given the initial estimates, the first run uses a diagonal variance-covariance matrix with all four parameters having a normally distributed random component and the model having additive residuals. The residual plot is shown in
This shows that the assumption about additive variance holds reasonably well and the residuals are centered around zero. Whilst the plot is not completely random at low frequencies, due for example to technical errors of measurements and inaccuracies associated with using the Cole equation to model bioelectrical impedance, this is considered acceptable.
This additive variance model can then be compared with the multiplicative and additive plus multiplicative error models. The residual plot was best when the additive error model was used.
The initial model can then be compared with different models having various fixed effects parameters. For example, the initial model can be compared with a model setting the parameter c to have no random component to it, that is having a fixed effect only. The likelihood ratio test for nested models can then be used to compare these models with the initial run. In this instance it was found that the initial run significantly increased the log-likelihood to justify having all parameters in the model.
The final step of the modeling process is to allow some or all of the random effects to have a log-normal distribution. This shows that found parameter estimates were not biologically plausible and can therefore be disregarded.
In the end, the initial model chosen to start the modeling process was the one chosen based on the above reasoning. It was also the model that provided the maximum value of the log-likelihood of (y; θ).
Using the model described above, the final estimates can be found in table 1, where the random effects are normally distributed around zero with variance SZ; a diagonal matrix with diagonal elements [ω12, . . . , and ω42] is the residual variance.
It will be appreciated that these values are derived from actual physical measurements and will therefore depend on collected data. The above values are therefore for the purpose of illustration only and are not intended to be limiting.
A coefficient of variation (CV %) is calculated by dividing the standard error of an estimate by its estimate and multiplying this by 100 to form a percentage. Typically, acceptable CV %'s for fixed parameters and random parameters are 20% and 50%, respectively. From the table 1, we can see that the CV %'s for our estimates are more than reasonable.
D-Optimal Design for Fixed Effects Model
Examining a design for one individual using the fixed effects model will now be described using the initial estimates found in the previous section, θ=[R0, Rinf, C, α]′=[861, 320, 2.4e−006, 0.649]′. The design which maximises the determinant of the information matrix is:
However, as described above, this is for the values shown in Table 1 and if different values are used, a different matrix will be determined.
D-optimality generally selects extreme values of covariates, but this also occurs to an extent due to the nature of the Cole equation. If
The calculation of the D-efficiency will be described below, providing an indication of the limitation of not accounting for between subject variability seen in the next section.
Mixed Effects
For the Cole equation, parameter estimates are known to vary between subjects, and accordingly a mixed effects model must be used.
For the purpose of this analysis it will be assumed that it is possible to administer electrical currents through the, body at frequencies [0, 1000] kHz, and obtain an accurate reading of bioelectrical impedance Thus, this can assume a model:
yi=f(θ,ξ)+sεi (15)
Using the initial estimates from the fixed effects model determined above, and shown in table 1, the following D-optimal design was found by maximizing the determinant of equation 11:
When forming the expected fisher information matrix for this design, C(E, V) is set to a block matrix of zeros. Then, under this assumption, the fixed and random effects of the model are independent.
The D-efficiency of the fixed effect design under the mixed effects model is 0.9692. Such a high efficiency of the fixed effects D-optimal design suggests that, in this case, accounting for between subject variance only marginally improves the ability to estimate the parameters of the Cole equation.
Dealing with Practical Limitations
With bioelectrical impedance studies, it is known that low and high frequencies produce more highly variable readings of bioimpedance compared with less extreme frequencies.
Two possible approaches to account for this variability will now be described. The first restricts the design space to exclude frequencies where readings of bioimpedance are inaccurate. The second allows the residual variance to depend on the frequency in some manner that mimics real life patterns.
D-optimal Design with Restricted Frequencies
The straight forward approach to dealing with such a variance structure is to avoid frequencies which produce highly variable bioimpedance measures. At present, such bioimpendance studies limit the frequencies to being between a variety of ranges due to this added variability. Examples of such ranges are [4, 200], [4, 500] and [4, 750]. These intervals, therefore are used to define restricted designs.
Allowing parameters to vary between individuals the following D-optimal designs were found for the above example:
The D-efficiencies of these restricted designs under the mixed effects models are also shown in table 2. As the range becomes more restricted, the efficiencies decrease. This is highlighted by the D-efficiencies of these designs, which suggest that, under the assumption of constant additive variance, restricting the frequencies to certain intervals creates a significant loss in our ability to estimate parameters precisely. Consequently we will be forced to sample more often in the restricted case to obtain as precise estimates as in the unrestricted case.
D-optimal Design with Variance Function
An assessment of the preferred model can be made by adding a variance function into the model that mimics the variance of bioimpedance in real life studies.
In this case, once the true variance structure has been captured by the function, the D-optimal design will provide the best estimates of the parameters. Inherent in this design will be the ideal range to restrict our frequencies, based on the variance function used.
To achieve this, a model of the following form is used:
yi=f(θi,ξi)+εi(s1+s2h(ξ1)) (16)
where h(ξi), a function of frequency, specifies the variance function.
Relaxing the assumption about constant variance of the residuals by forming a variance function described above, allows accurate capture and mimicking of the residual structure, without violating any nonlinear regression assumptions.
Bioimpedance is made up of two parts, resistance and reactance, relating to the real and imaginary parts of the Cole equation, respectively. An example plot of resistance vs reactance is shown in
The peak of the locus of the semi-circle identifies the characteristic frequency fc. This frequency yields the smallest variance due to the variance function and consequently, it is assumed that at this frequency the constant additive variance dominates. The variance function needs to be such that there is relatively small variance between the chosen interval, for example [4, 750], with rapidly increasing variance for frequencies outside these bounds.
Accordingly, a double exponential model, centred around fc, can be used to adequately model the variance of such a study. Thus, for the range 0 kHz to 1000 kHz, frequencies between fc and 1000 are rescaled to be between 0 and 1. Similarly, frequencies between 0 and fc are rescaled so that they are between 1 and 0. The new vector of rescaled frequencies is then exponentiated twice, and scaled such that the vector has a minimum and a maximum at 0 and 1, respectively. Finally, slightly extra variability is added to frequencies greater than fc by multiplying the resealed numbers which relate to these frequencies by 2. This whole vector is then multiplied by σextra2.
Example residual plots of this variance function h(ξ) for various σextra2 values are shown in
From this it can be seen that the actual structure of the function does not change, but is merely at a different scale. This also shows how variable readings of bioimpedance can be at low and high frequencies, particularly when σextra2 is large, and how there exists relatively small variance between 4 and 750.
This leads to another consideration for this variance structure, in particular, how much should bioimpedance vary at low and high frequencies, and therefore how large should σextra2 be such that it will capture the real life variance structure of bioimpedance.
Table 3 shows D-optimal designs found for various values of σextra2. The D-efficiencies shown refer to the efficiency of each design compared with the D-optimal design described above. For all designs, the model considered is from equation 16.
This shows that as the variance increases at the low and high frequencies, the criterion starts to choose frequencies at the less extreme values, thereby avoiding regions which relate to a highly variable reading of bioimpedance. Thus, it is up of the experimenter to decide how variable bioimpedance can be. Once this is decided, the D-optimal design will take this variability into account and find the design which will give the best estimates of parameters.
For example, at a first instance, a broad set of preferred frequency ranges can be defined as follows:
However, using a more limited design space based on the above mentioned practical constraints can lead to more specific frequency ranges as follows:
In a more extreme limitation, for example, assuming σ2=0.2 is a true representation of the variance, then the optimal design can be seen in the above table, indicating that measurements at frequencies lower than 14.64 kHz and higher than 680.60 kHz are too variable and should be avoided.
Uncertainty in Prior Estimates
Inaccurate prior estimates of parameters for nonlinear models can lead to designs that have a limited ability to estimate parameters that diverse considerably from what was expected. In order to find a design that offers efficient parameter estimates across a wide range of prior estimates, we can look at product design optimality discussed above.
A product design is generally more robust to changes in initial parameter estimates than local D-optimal designs for each parameter set. Thus, a product design is preferred if uncertainty exists in the initial parameter estimates.
Product Design
Given the initial parameters estimates above, 5th and 95th percentiles of the population can be found using the estimates of the between subject variability. For example, given the initial estimate of R0=861 with ω1=138, the 5th and 95th percentiles would be 584 and 1138, respectively.
Such percentiles can be determined for all four model parameters giving a set of eight different initial estimates which would be used as eight different impedance models in the product design. The eight parameter sets considered can be seen in table 4.
0.6490 ′
The product design is formed by optimizing over the product of the determinants of the respective variance-covariance matrices of the eight models as a single function. The idea behind forming product designs in this way is that optimizing across all eight models will provide a design which is efficient across a wide range of parameter estimates. The model considered is of the form of equation 16 (σextra2=0.2), the values for which are set out in Table 3 as:
The following product design is given by:
Design Evaluation
To analyze how efficient the product design is at estimating parameters across all models, the efficiency of the design under each model is determined, as shown in table 5, in which the efficiency of the product design is compared to each D-optimal design for each parameter set.
The efficiency of the product design can be calculated by comparing its D-value under each model compared to the D-optimal value under the respective model. Table 5 shows the efficiency of the product design compared to each D-optimal design for each parameter set. Relatively high efficiencies across all models suggest that the product design is a good means for allowing for uncertainty in initial parameter estimates. Further, given the range of parameter values considered, it is believed that these designs will efficiently estimate model parameters for a variety of individuals. Hence, this approach and the frequencies found should benefit bioimpedance analysis.
A practical approach, applies real data to determine how well model parameters can be estimated. Given the design:
and the data on 61 individuals, impedance at these frequencies were extracted from the data set of all individuals and a nonlinear mixed effects model was fitted to this extracted data set.
Using the same model and initial parameter estimates as discussed in the modelling section above, MONOLIX provides estimates for the parameter values as shown in table 6 and estimates of coefficients of variation found in table 7.
The new estimates shown in table 6 are similar to those found using the full data set of observations. Given this and the residual plot, it is concluded that this D-optimal design performs well in practice and as such, with the use of only four frequencies, we have been able to form estimates of parameters of the Cole equation similar to those found by using the full data set.
It is also clear that the product design performs well in practice and requires of only four is frequencies per individual. That is, the optimal choice of these frequencies yields the ability to efficiently estimate model parameters. Further, it highlights the apparent lack of information gained by choosing over 100 unique frequencies per individual to model bioimpedance.
Table 7 shows that the coefficients of variation estimated from the full data set are similar to those estimated from the extracted data set. This suggests that only four measurements of impedance per individual are needed to efficiently estimate the parameters of the Cole equation.
Table 7 also shows the expected coefficients of variation calculated by using the expected Fisher information matrix to form the expected standard errors of estimates.
Accordingly, this shows that experimental design for nonlinear fixed and mixed effects models can be applied BIA, allowing preferred frequency measuring models to be determined. Numerous four frequency designs were found relating to D-optimal designs based on various assumptions about how frequency relates to bioimpedance and how parameters vary between individuals. Product designs were also found. These designs should be robust to changes in initial estimates.
D-optimal designs can also be applied to real data where it was shown to perform well against the full data set. It is hoped that the D-optimal design approach used here and the designs found will aid BIA researchers in the design of optimised multiple frequency BIA instrumentation. This will mitigate the acknowledged inadequacy of some currently used instrumentation and provide for better clinical utility, for example, the accurate prediction of lean body mass for drug dosing in the obese.
Persons skilled in the art will appreciate that numerous variations and modifications will become apparent. All such variations and modifications which become apparent to persons skilled in the art, should be considered to fall within the spirit and scope that the invention broadly appearing before described.
Number | Date | Country | Kind |
---|---|---|---|
2006902907 | May 2006 | AU | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/AU2007/000726 | 5/25/2007 | WO | 00 | 11/23/2009 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2007/137333 | 12/6/2007 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3316896 | Thomasset | May 1967 | A |
3834374 | Ensanian et al. | Sep 1974 | A |
3851641 | Toole et al. | Dec 1974 | A |
3871359 | Pacela | Mar 1975 | A |
4008712 | Nyboer | Feb 1977 | A |
4034854 | Bevilacqua | Jul 1977 | A |
4144878 | Wheeler | Mar 1979 | A |
RE30101 | Kubicek et al. | Sep 1979 | E |
4184486 | Papa | Jan 1980 | A |
4291708 | Frei et al. | Sep 1981 | A |
4314563 | Wheeler | Feb 1982 | A |
4353372 | Ayer | Oct 1982 | A |
4365634 | Bare et al. | Dec 1982 | A |
4401356 | Bare | Aug 1983 | A |
4407288 | Langer et al. | Oct 1983 | A |
4407300 | Davis | Oct 1983 | A |
4450527 | Sramek | May 1984 | A |
4458694 | Sollish et al. | Jul 1984 | A |
4486835 | Bai et al. | Dec 1984 | A |
4537203 | Machida | Aug 1985 | A |
4539640 | Fry et al. | Sep 1985 | A |
4557271 | Stoller et al. | Dec 1985 | A |
4583549 | Manoli | Apr 1986 | A |
4602338 | Cook | Jul 1986 | A |
4617939 | Brown et al. | Oct 1986 | A |
4646754 | Seale | Mar 1987 | A |
4686477 | Givens et al. | Aug 1987 | A |
4688580 | Ko et al. | Aug 1987 | A |
4695955 | Faisandier | Sep 1987 | A |
4763660 | Kroll et al. | Aug 1988 | A |
4793362 | Tedner | Dec 1988 | A |
4832608 | Kroll | May 1989 | A |
4890630 | Kroll et al. | Jan 1990 | A |
4895163 | Libke et al. | Jan 1990 | A |
4905705 | Kizakevich et al. | Mar 1990 | A |
4911175 | Shizgal | Mar 1990 | A |
4924875 | Chamoun | May 1990 | A |
4942880 | Slovak | Jul 1990 | A |
4951682 | Petre | Aug 1990 | A |
5025784 | Shao et al. | Jun 1991 | A |
5063937 | Ezenwa et al. | Nov 1991 | A |
5078134 | Heilman et al. | Jan 1992 | A |
5086781 | Bookspan | Feb 1992 | A |
5101828 | Welkowitz et al. | Apr 1992 | A |
5143079 | Frei et al. | Sep 1992 | A |
5197479 | Hubelbank et al. | Mar 1993 | A |
5199432 | Quedens et al. | Apr 1993 | A |
5246008 | Mueller | Sep 1993 | A |
5280429 | Withers | Jan 1994 | A |
5305192 | Bonte et al. | Apr 1994 | A |
5309917 | Wang et al. | May 1994 | A |
5311878 | Brown et al. | May 1994 | A |
5372141 | Gallup et al. | Dec 1994 | A |
5415164 | Faupel et al. | May 1995 | A |
5421344 | Popp | Jun 1995 | A |
5423326 | Wang et al. | Jun 1995 | A |
5449000 | Libke et al. | Sep 1995 | A |
5454377 | Dzwonczyk et al. | Oct 1995 | A |
5465730 | Zadehkoochak et al. | Nov 1995 | A |
5469859 | Tsoglin et al. | Nov 1995 | A |
5503157 | Sramek | Apr 1996 | A |
5505209 | Reining | Apr 1996 | A |
5511553 | Segalowitz | Apr 1996 | A |
5526808 | Kaminsky | Jun 1996 | A |
5529072 | Sramek | Jun 1996 | A |
5544662 | Saulnier et al. | Aug 1996 | A |
5557242 | Wetherell | Sep 1996 | A |
5562607 | Gyory | Oct 1996 | A |
5588429 | Isaacson et al. | Dec 1996 | A |
5596283 | Mellitz et al. | Jan 1997 | A |
5626146 | Barber et al. | May 1997 | A |
5679022 | Cappa et al. | Oct 1997 | A |
5704355 | Bridges | Jan 1998 | A |
5718231 | Dewhurst et al. | Feb 1998 | A |
5732710 | Rabinovich et al. | Mar 1998 | A |
5735284 | Tsoglin et al. | Apr 1998 | A |
5746214 | Brown et al. | May 1998 | A |
5759159 | Masreliez | Jun 1998 | A |
5788643 | Feldman | Aug 1998 | A |
5800350 | Coppleson et al. | Sep 1998 | A |
5807251 | Wang et al. | Sep 1998 | A |
5807270 | Williams | Sep 1998 | A |
5807272 | Kun et al. | Sep 1998 | A |
5810742 | Pearlman | Sep 1998 | A |
5876353 | Riff | Mar 1999 | A |
5906614 | Stern et al. | May 1999 | A |
5919142 | Boone et al. | Jul 1999 | A |
5957861 | Combs et al. | Sep 1999 | A |
6006125 | Kelly et al. | Dec 1999 | A |
6011992 | Hubbard et al. | Jan 2000 | A |
6015389 | Brown | Jan 2000 | A |
6018677 | Vidrine et al. | Jan 2000 | A |
6026323 | Skladnev et al. | Feb 2000 | A |
6122544 | Organ | Sep 2000 | A |
6125297 | Siconolfi | Sep 2000 | A |
6142949 | Ubby | Nov 2000 | A |
6151520 | Combs | Nov 2000 | A |
6151523 | Ferrer et al. | Nov 2000 | A |
6173003 | Whikehart et al. | Jan 2001 | B1 |
6208890 | Sarrazin et al. | Mar 2001 | B1 |
6228033 | Koobi et al. | May 2001 | B1 |
6233473 | Shepherd et al. | May 2001 | B1 |
6236886 | Cherepenin et al. | May 2001 | B1 |
6248083 | Smith et al. | Jun 2001 | B1 |
6256532 | Cha | Jul 2001 | B1 |
6292690 | Petrucelli et al. | Sep 2001 | B1 |
6339722 | Heethaar et al. | Jan 2002 | B1 |
6354996 | Drinan et al. | Mar 2002 | B1 |
6469732 | Chang et al. | Oct 2002 | B1 |
6472888 | Oguma et al. | Oct 2002 | B2 |
6496725 | Kamada et al. | Dec 2002 | B2 |
6497659 | Rafert | Dec 2002 | B1 |
6511438 | Bernstein et al. | Jan 2003 | B2 |
6512949 | Combs et al. | Jan 2003 | B1 |
6532384 | Fukuda | Mar 2003 | B1 |
6551252 | Sackner et al. | Apr 2003 | B2 |
6556001 | Wiegand et al. | Apr 2003 | B1 |
6560480 | Nachaliel et al. | May 2003 | B1 |
6561986 | Baura et al. | May 2003 | B2 |
6569160 | Goldin et al. | May 2003 | B1 |
6584348 | Glukhovsky | Jun 2003 | B2 |
6602201 | Hepp et al. | Aug 2003 | B1 |
6615077 | Zhu et al. | Sep 2003 | B1 |
6618616 | Iijima et al. | Sep 2003 | B2 |
6623312 | Merry et al. | Sep 2003 | B2 |
6625487 | Herleikson | Sep 2003 | B2 |
6631292 | Liedtke | Oct 2003 | B1 |
6633777 | Szopinski | Oct 2003 | B2 |
6636754 | Baura et al. | Oct 2003 | B1 |
6643543 | Takehara et al. | Nov 2003 | B2 |
6714813 | Ishigooka et al. | Mar 2004 | B2 |
6714814 | Yamada et al. | Mar 2004 | B2 |
6723049 | Skladnev et al. | Apr 2004 | B2 |
6724200 | Fukuda | Apr 2004 | B2 |
6725089 | Komatsu et al. | Apr 2004 | B2 |
6753487 | Fujii et al. | Jun 2004 | B2 |
6760617 | Ward et al. | Jul 2004 | B2 |
6768921 | Organ et al. | Jul 2004 | B2 |
6790178 | Mault et al. | Sep 2004 | B1 |
6807443 | Keren | Oct 2004 | B2 |
6829501 | Nielsen et al. | Dec 2004 | B2 |
6829503 | Alt | Dec 2004 | B2 |
6845264 | Skladnev et al. | Jan 2005 | B1 |
6870109 | Villarreal | Mar 2005 | B1 |
6906533 | Yoshida | Jun 2005 | B1 |
6922586 | Davies | Jul 2005 | B2 |
6980852 | Jersey-Willuhn et al. | Dec 2005 | B2 |
7096061 | Arad | Aug 2006 | B2 |
7122012 | Bouton et al. | Oct 2006 | B2 |
7130680 | Kodama et al. | Oct 2006 | B2 |
7148701 | Park et al. | Dec 2006 | B2 |
7149573 | Wang | Dec 2006 | B2 |
7164522 | Kimura et al. | Jan 2007 | B2 |
7169107 | Jersey-Willuhn et al. | Jan 2007 | B2 |
7184820 | Jersey-Willuhn et al. | Feb 2007 | B2 |
7184821 | Belalcazar et al. | Feb 2007 | B2 |
7186220 | Stahmann et al. | Mar 2007 | B2 |
7212852 | Smith et al. | May 2007 | B2 |
7214107 | Powell et al. | May 2007 | B2 |
7233823 | Simond et al. | Jun 2007 | B2 |
7251524 | Hepp et al. | Jul 2007 | B1 |
7270580 | Bradley et al. | Sep 2007 | B2 |
7353058 | Weng et al. | Apr 2008 | B2 |
7390303 | Dafni | Jun 2008 | B2 |
7457660 | Smith et al. | Nov 2008 | B2 |
7477937 | Iijima et al. | Jan 2009 | B2 |
7706872 | Min et al. | Apr 2010 | B2 |
7733224 | Tran | Jun 2010 | B2 |
7749013 | Sato et al. | Jul 2010 | B2 |
7907997 | Stahmann et al. | Mar 2011 | B2 |
20010007056 | Linder et al. | Jul 2001 | A1 |
20010007924 | Kamada et al. | Jul 2001 | A1 |
20010020138 | Ishigooka et al. | Sep 2001 | A1 |
20010025139 | Pearlman | Sep 2001 | A1 |
20010049479 | Szopinski | Dec 2001 | A1 |
20010051774 | Littrup et al. | Dec 2001 | A1 |
20020022787 | Takehara et al. | Feb 2002 | A1 |
20020072682 | Hopman et al. | Jun 2002 | A1 |
20020072686 | Hoey et al. | Jun 2002 | A1 |
20020079910 | Fukuda | Jun 2002 | A1 |
20020093992 | Plangger | Jul 2002 | A1 |
20020123694 | Organ et al. | Sep 2002 | A1 |
20020138019 | Wexler et al. | Sep 2002 | A1 |
20020161311 | Ward et al. | Oct 2002 | A1 |
20020163408 | Fujii et al. | Nov 2002 | A1 |
20020194419 | Rajput et al. | Dec 2002 | A1 |
20030004403 | Drinan et al. | Jan 2003 | A1 |
20030004433 | Hirschman | Jan 2003 | A1 |
20030023184 | Pitts-Crick et al. | Jan 2003 | A1 |
20030028221 | Zhu et al. | Feb 2003 | A1 |
20030050570 | Kodama | Mar 2003 | A1 |
20030068914 | Merry et al. | Apr 2003 | A1 |
20030073916 | Yonce | Apr 2003 | A1 |
20030105411 | Smallwood | Jun 2003 | A1 |
20030120170 | Zhu et al. | Jun 2003 | A1 |
20030120182 | Wilkinson et al. | Jun 2003 | A1 |
20030173976 | Wiegand et al. | Sep 2003 | A1 |
20030216664 | Suarez | Nov 2003 | A1 |
20040015095 | Li | Jan 2004 | A1 |
20040019292 | Drinan et al. | Jan 2004 | A1 |
20040054298 | Masuo et al. | Mar 2004 | A1 |
20040059242 | Masuo et al. | Mar 2004 | A1 |
20040073127 | Istvan et al. | Apr 2004 | A1 |
20040073130 | Bohm et al. | Apr 2004 | A1 |
20040077944 | Steinberg et al. | Apr 2004 | A1 |
20040116819 | Alt | Jun 2004 | A1 |
20040158167 | Smith et al. | Aug 2004 | A1 |
20040167423 | Pillon et al. | Aug 2004 | A1 |
20040171963 | Takehara | Sep 2004 | A1 |
20040181164 | Smith et al. | Sep 2004 | A1 |
20040186392 | Ward et al. | Sep 2004 | A1 |
20040204658 | Dietz et al. | Oct 2004 | A1 |
20040210150 | Virtanen | Oct 2004 | A1 |
20040210158 | Organ et al. | Oct 2004 | A1 |
20040234113 | Miga | Nov 2004 | A1 |
20040236202 | Burton | Nov 2004 | A1 |
20040242989 | Zhu et al. | Dec 2004 | A1 |
20040252870 | Reeves et al. | Dec 2004 | A1 |
20040260167 | Leonhardt et al. | Dec 2004 | A1 |
20050033281 | Bowman et al. | Feb 2005 | A1 |
20050039763 | Kraemer et al. | Feb 2005 | A1 |
20050070778 | Lackey et al. | Mar 2005 | A1 |
20050080460 | Wang et al. | Apr 2005 | A1 |
20050098343 | Fukuda | May 2005 | A1 |
20050101875 | Semler et al. | May 2005 | A1 |
20050107719 | Arad (Abbound) et al. | May 2005 | A1 |
20050113704 | Lawson et al. | May 2005 | A1 |
20050117196 | Kimura et al. | Jun 2005 | A1 |
20050124908 | Belalcazar et al. | Jun 2005 | A1 |
20050137480 | Alt et al. | Jun 2005 | A1 |
20050151545 | Park et al. | Jul 2005 | A1 |
20050177062 | Skrabal et al. | Aug 2005 | A1 |
20050192488 | Bryenton et al. | Sep 2005 | A1 |
20050192511 | Shiokawa | Sep 2005 | A1 |
20050201598 | Harel et al. | Sep 2005 | A1 |
20050203435 | Nakada | Sep 2005 | A1 |
20050215918 | Frantz et al. | Sep 2005 | A1 |
20050228309 | Fisher et al. | Oct 2005 | A1 |
20050261743 | Kroll | Nov 2005 | A1 |
20050283091 | Kink et al. | Dec 2005 | A1 |
20060004300 | Kennedy | Jan 2006 | A1 |
20060041280 | Stahmann et al. | Feb 2006 | A1 |
20060064029 | Arad (Abboud) et al. | Mar 2006 | A1 |
20060085048 | Cory et al. | Apr 2006 | A1 |
20060085049 | Cory et al. | Apr 2006 | A1 |
20060110962 | Powell et al. | May 2006 | A1 |
20060111652 | McLeod | May 2006 | A1 |
20060116599 | Davis | Jun 2006 | A1 |
20060122523 | Bonmassar et al. | Jun 2006 | A1 |
20060122540 | Zhu et al. | Jun 2006 | A1 |
20060128193 | Bradley et al. | Jun 2006 | A1 |
20060135886 | Lippert et al. | Jun 2006 | A1 |
20060151815 | Graovac et al. | Jul 2006 | A1 |
20060197509 | Kanamori et al. | Sep 2006 | A1 |
20060200033 | Keren et al. | Sep 2006 | A1 |
20060224079 | Washchuk | Oct 2006 | A1 |
20060224080 | Oku et al. | Oct 2006 | A1 |
20060241513 | Hatlestad et al. | Oct 2006 | A1 |
20060241719 | Foster et al. | Oct 2006 | A1 |
20060247543 | Cornish et al. | Nov 2006 | A1 |
20060247739 | Wahlstrand et al. | Nov 2006 | A1 |
20060258952 | Stahmann et al. | Nov 2006 | A1 |
20060264775 | Mills et al. | Nov 2006 | A1 |
20060264776 | Stahmann et al. | Nov 2006 | A1 |
20060270942 | McAdams | Nov 2006 | A1 |
20060293609 | Stahmann et al. | Dec 2006 | A1 |
20070007975 | Hawkins et al. | Jan 2007 | A1 |
20070010758 | Matthiessen et al. | Jan 2007 | A1 |
20070027402 | Levin et al. | Feb 2007 | A1 |
20070043303 | Osypka et al. | Feb 2007 | A1 |
20070049993 | Hofmann et al. | Mar 2007 | A1 |
20070087703 | Li et al. | Apr 2007 | A1 |
20070106342 | Schumann | May 2007 | A1 |
20070156061 | Hess | Jul 2007 | A1 |
20080001608 | Saulnier et al. | Jan 2008 | A1 |
20080002873 | Reeves et al. | Jan 2008 | A1 |
20080004904 | Tran | Jan 2008 | A1 |
20080009757 | Tsoglin et al. | Jan 2008 | A1 |
20080009759 | Chetham | Jan 2008 | A1 |
20080039700 | Drinan et al. | Feb 2008 | A1 |
20080064981 | Gregory | Mar 2008 | A1 |
20080205717 | Reeves et al. | Aug 2008 | A1 |
20080252304 | Woo et al. | Oct 2008 | A1 |
20080270051 | Essex et al. | Oct 2008 | A1 |
20080287823 | Chetham | Nov 2008 | A1 |
20080319336 | Ward et al. | Dec 2008 | A1 |
20090043222 | Chetham | Feb 2009 | A1 |
20090054952 | Glukhovsky et al. | Feb 2009 | A1 |
20090076343 | James et al. | Mar 2009 | A1 |
20090076345 | Manicka et al. | Mar 2009 | A1 |
20090076350 | Bly et al. | Mar 2009 | A1 |
20090082679 | Chetham | Mar 2009 | A1 |
20090084674 | Holzhacker et al. | Apr 2009 | A1 |
20090105555 | Dacso et al. | Apr 2009 | A1 |
20090143663 | Chetham | Jun 2009 | A1 |
20090177099 | Smith et al. | Jul 2009 | A1 |
20090264776 | Vardy | Oct 2009 | A1 |
20090287102 | Ward | Nov 2009 | A1 |
20090318778 | Dacso et al. | Dec 2009 | A1 |
20100100003 | Chetham et al. | Apr 2010 | A1 |
20100109739 | Ironstone et al. | May 2010 | A1 |
20100145164 | Howell | Jun 2010 | A1 |
20100168530 | Chetham et al. | Jul 2010 | A1 |
20100234701 | Cho et al. | Sep 2010 | A1 |
20110060239 | Gaw | Mar 2011 | A1 |
Number | Date | Country |
---|---|---|
2231038 | Nov 1999 | CA |
2613524 | Jan 2007 | CA |
2615845 | Jan 2007 | CA |
1180513 | May 1998 | CN |
1236597 | Dec 1999 | CN |
1329875 | Jan 2002 | CN |
1366694 | Aug 2002 | CN |
101385203 | Mar 2009 | CN |
2912349 | Oct 1980 | DE |
249823 | Dec 1987 | EP |
339471 | Nov 1989 | EP |
349043 | Jan 1990 | EP |
357309 | Mar 1990 | EP |
377887 | Jul 1990 | EP |
581073 | Feb 1994 | EP |
662311 | Jul 1995 | EP |
865763 | Sep 1998 | EP |
869360 | Oct 1998 | EP |
1078597 | Feb 2001 | EP |
1080686 | Mar 2001 | EP |
1112715 | Jul 2001 | EP |
1114610 | Jul 2001 | EP |
1146344 | Oct 2001 | EP |
1177760 | Feb 2002 | EP |
1219937 | Jul 2002 | EP |
1238630 | Sep 2002 | EP |
1247487 | Oct 2002 | EP |
1283539 | Feb 2003 | EP |
1329190 | Jul 2003 | EP |
1338246 | Aug 2003 | EP |
1452131 | Sep 2004 | EP |
1553871 | Jul 2005 | EP |
1629772 | Mar 2006 | EP |
1903938 | Apr 2008 | EP |
1909642 | Apr 2008 | EP |
1948017 | Jul 2008 | EP |
2486386 | Jan 1982 | FR |
2748928 | Nov 1997 | FR |
2131558 | Jun 1984 | GB |
2260416 | Apr 1993 | GB |
2426824 | Dec 2006 | GB |
04-096733 | Mar 1992 | JP |
06-000168 | Jan 1994 | JP |
8191808 | Jul 1996 | JP |
9051884 | Feb 1997 | JP |
9220209 | Aug 1997 | JP |
10000185 | Jan 1998 | JP |
10014898 | Jan 1998 | JP |
10014899 | Jan 1998 | JP |
10-080406 | Mar 1998 | JP |
10-225521 | Aug 1998 | JP |
11070090 | Mar 1999 | JP |
2000107138 | Apr 2000 | JP |
2000139867 | May 2000 | JP |
2001037735 | Feb 2001 | JP |
2001-070273 | Mar 2001 | JP |
2001061804 | Mar 2001 | JP |
2001-224568 | Aug 2001 | JP |
2001321352 | Nov 2001 | JP |
2002330938 | Nov 2002 | JP |
2003116805 | Apr 2003 | JP |
2005099186 | Apr 2005 | JP |
2005-143786 | Jun 2005 | JP |
2008022995 | Feb 2008 | JP |
001019789 | Jul 2003 | NL |
2112416 | Jun 1998 | RU |
2138193 | Sep 1999 | RU |
1132911 | Jan 1985 | SU |
8807392 | Oct 1988 | WO |
9318821 | Sep 1993 | WO |
9410922 | May 1994 | WO |
9601586 | Jan 1996 | WO |
9612439 | May 1996 | WO |
9632652 | Oct 1996 | WO |
9711638 | Apr 1997 | WO |
9714358 | Apr 1997 | WO |
9743000 | Nov 1997 | WO |
9806328 | Feb 1998 | WO |
9823204 | Jun 1998 | WO |
9833553 | Aug 1998 | WO |
9851211 | Nov 1998 | WO |
9854792 | Dec 1998 | WO |
0019886 | Apr 2000 | WO |
0040955 | Jul 2000 | WO |
0079255 | Dec 2000 | WO |
0127605 | Apr 2001 | WO |
0150954 | Jul 2001 | WO |
0167098 | Sep 2001 | WO |
0178831 | Oct 2001 | WO |
0182323 | Nov 2001 | WO |
0247548 | Jun 2002 | WO |
02062214 | Aug 2002 | WO |
02094096 | Nov 2002 | WO |
02100267 | Dec 2002 | WO |
2004000115 | Dec 2003 | WO |
2004026136 | Apr 2004 | WO |
2004030535 | Apr 2004 | WO |
2004032738 | Apr 2004 | WO |
2004047636 | Jun 2004 | WO |
2004048983 | Jun 2004 | WO |
2004047635 | Jun 2004 | WO |
2004047638 | Jun 2004 | WO |
2004049936 | Jun 2004 | WO |
2004083804 | Sep 2004 | WO |
2004084723 | Oct 2004 | WO |
2004084724 | Oct 2004 | WO |
2005010640 | Feb 2005 | WO |
2005018432 | Mar 2005 | WO |
2005027717 | Mar 2005 | WO |
2005051194 | Jun 2005 | WO |
2005084539 | Sep 2005 | WO |
2005122888 | Dec 2005 | WO |
2005122881 | Dec 2005 | WO |
2006129108 | Dec 2006 | WO |
2006129116 | Dec 2006 | WO |
2007002993 | Jan 2007 | WO |
2007002991 | Jan 2007 | WO |
2007002992 | Jan 2007 | WO |
2007009183 | Jan 2007 | WO |
2007014417 | Feb 2007 | WO |
2007041783 | Apr 2007 | WO |
2007089278 | Aug 2007 | WO |
2008064426 | Jun 2008 | WO |
2008119166 | Oct 2008 | WO |
2008138062 | Nov 2008 | WO |
2009036369 | Mar 2009 | WO |
2009059351 | May 2009 | WO |
2009100491 | Aug 2009 | WO |
2010051600 | May 2010 | WO |
2010060152 | Jun 2010 | WO |
2011022068 | Feb 2011 | WO |
2011050393 | May 2011 | WO |
2011075769 | Jun 2011 | WO |
Entry |
---|
Liu et al., Primary Multi-frequency Data Analyze in Electrical Impedance Scanning, Proceedings of the IEEE-EMBS 2005, 27th Annual Int'l Conference of the Engineering in Med. and Biology Soc., Shanghai, China, Sep. 4, 2005; 1504-1507. |
Gudivaka et al., Single- and multifrequency models for bioelectrical impedance analysis of body water compartments, Appl. Physiol., 1999; 87(3), 1087-96. |
U.S. Appl. No. 13/128,631, Essex et al. |
U.S. Appl. No. 13/131,859, Gaw. |
U.S. Appl. No. 12/090,078, filed Feb. 12, 2009, Chetham. |
U.S. Appl. No. 12/516,876, filed Jul. 1, 2010, Chetham. |
U.S. Appl. No. 12/596,833, filed Jun. 17, 2010, Ward. |
U.S. Appl. No. 12/600,224, Chetham. |
U.S. Appl. No. 12/672,893, filed Feb. 24, 2011, Cornish. |
U.S. Appl. No. 10/767,825, filed Sep. 23, 2004, Ward. |
d'Entremont et al. “Impedance spectroscopy: an accurate method of differentiating between viable and ischaemic or infarcted muscle tissue” Med. Biol. Eng. Comput., 2002, 40: 380-87. |
Zhu et al., “Dynamics of segmental extracellular volumes during changes in body position by bioimpedance analysis”; J. App. Physiol.; 1998, vol. 85, pp. 497-504. |
McCullagh, W. A., et al., Bioelectrical impedance analysis measures the ejection fraction of the calf muscle pump, IFMBE Proceedings, 2007; vol. 17, p. 619. |
European Search Report for EP 07718972.8-1265 / 2020918 (Impedimed, Ltd.), mailed on Mar. 2, 2010, 4 pages. |
Brown et al.; Relation between tissue structure and imposed electrical current flow in cervical neoplasis; The Lancet; Mar. 11, 2000; vol. 355, Issue 9207: pp. 892-895. |
Ellis et al.; Human hydrometry: comparison of multifrequency biolectrical impedance with 2H2O and bromine dilution; Journal of Applied Physiology; 1998; 85(3): 1056-1062. |
Jones et al.; Extracellular fluid volume determined by bioelectric impedance and serum albumin in CAPD patients; Nephrology Dialysis Transplantation; 1998; 13: 393-397. |
Thomas B.J.; Future technologies; Asia Pacific Journal Clinical Nutrition; 1995; 4: 157-159. |
Schneider, I.; Broadband signals for electrical impedance measurements for long bone fractures; Engineering in Medicine and Biology Society, 1996. Bridging Disciplines for Biomedicine. Proceedings of the 18th Annual International Conference of the IEEE; Oct. 31, 1996; 5: 1934-1935. |
Woodrow et al.; Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis; Nephrology Dialysis Transplantation; 2000; 15: 862-866. |
Boulier et al.; Fat-Free Mass Estimation by Two Electrode Impedance Method; American Journal of Clinical Nutrition; 1990; 52: 581-585. |
McDougal et al.; Body Composition Measurements from Whole Body Resistance and Reactance; Surgical Forum; 1986; 36: 43-44. |
Tedner, B.; Equipment using Impedance Technique for Automatic Recording of Fluid-Volume Changes during Hemodialysis; Medical & Biological Engineering & Computing; 1983; 285-290. |
Lukaski et al.; Estimation of Body Fluid Volumes using Tetrapolar Bioelectrical Impedance Measurements; Aviation, Space, and Environmental Medicine; Dec. 1988; 1163-1169. |
Lozano et al.; Two-frequency impedance plethysmograph: real and imaginary parts; Medical & Biological Engineering & Computing; Jan. 1990; 28(1): 38-42. |
Chaudary et al.; Dielectric Properties of Normal & Malignant Human Breast Tissues at Radiowave and Microwave Frequencies; Indian Journal of Biochemistry & Biophysics; 1984; 21(1): 76-79. |
Jossinet et al.; A study for breast imaging with a circular array of impedance electrodes; Proc. Vth Int. Conf. Bioelectrical Impedance, 1981, Tokyo, Japan; 1981; 83-86. |
Jossinet et al.; Technical Implementation and Evaluation of a Bioelectrical Breast Scanner; Proc. 10.supth Int. Conf. IEEE Engng. Med. Biol., 1988, New Orleans, USA (Imped. Imaging II); 1988; 1: 289. |
Man et al.; Results of Preclinical Tests for Breast Cancer Detection by Dielectric Measurements; XII Int. Conf. Med. Biol. Engng. 1979, Jerusalem, Israel. Springer Int., Berlin; 1980; Section 30.4. |
Pethig et al.; The Passive Electrical Properties of Biological Systems: Their Significance in Physiology, Biophysics and Biotechnology; Physics in Medicine and Biology; 1987; 32: 933-970. |
Piperno et al.; Breast Cancer Screening by Impedance Measurements; Frontiers of Medical & Biological Engineering; 1990; 2: 111-117. |
Skidmore et al.; A Data Collection System for Gathering Electrical Impedance Measurements from the Human Breast; Clinical Physics Physiological Measurement; 1987; 8: 99-102. |
Sollish et al.; Microprocessor-assisted Screening Techniques; Israel Journal of Medical Sciences; 1981; 17: 859-864. |
Surowiec et al.; Dielectric Properties of Breast Carcinima and the Surrounding Tissues; IEEE Transactions on Biomedical Engineering; 1988; 35: 257-263. |
Al-Hatib, F.; Patient Instrument Connection Errors in Bioelectrical Impedance Measurement; Physiological Measurement; May 2, 1998; 19(2): 285-296. |
Gersing, E.; Impedance Spectroscopy on Living Tissue for Determination of the State of Organs; Bioelectrochemistry and Bioenergetics; 1998; 45: 145-149. |
Mattar, J.A.; Application of Total Body Impedance to the Critically Ill Patient; New Horizons; 1996; 4(4): 493-503. |
Ott et al.; Bioelectrical Impedance Analysis as a Predictor of Survival in Patients with Human Immunodeficiency Virus Infection; Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology; 1995; 9: 20-25. |
Thomas et al.; Bioelectrical impedance analysis for measurement of body fluid volumes—a review; Journal of Clinical Engineering; 1992; 17(16): 505-510. |
Ward et al.; There is a better way to measure Lymphedema; National Lymphedema Network Newsletter; Oct. 1995; 7(4): 89-92. |
Cornish et al.; Alteration of the extracellular and total body water volumes measured by multiple frequency bioelectrical impedance analysis; Nutrition Research; 1994; 14(5): 717-727. |
Cornish et al.; Early diagnosis of lymphedema using multiple frequency bioimpedance; Lymphology; Mar. 2001; 34: 2-11. |
Cornish et al.; Early diagnosis of lymphoedema in postsurgery breast cancer patients; Annals New York Academy of Sciences; May 2000; 571-575. |
Brown et al.; Relation between tissue structure and imposed electrical current flow in cervical neoplasia; The Lancet; Mar. 11, 2000; 355 (9207): 892-895. |
Iacobellis, G. et al.; Influence of excess fat on cardiac morphology and function: Study in Uncomplicated obesity; Obesity Research; Aug. 8, 2002; 10 (8): 767-773. |
Bella, J. N. et al.; Relations of left ventricular mass to fat-free and adipose body mass: The Strong Heart Study; Circulation; Dec. 12, 1998; 98: 2538-2544. |
Yoshinaga, M. et al.; Effect of total adipose weight and systemic hypertension on left ventricular mass in children; American Journal of Cardiology; Oct. 15, 1995; 76: 785-787. |
Karason, K. et al.; Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure; European Heart Journal; Jan. 1, 2003; 24: 1500-1505. |
Abdullah M. Z.; Simulation of an inverse problem in electrical impedance tomography using resistance electrical network analogues; International Journal of Electrical Engineering Education; Oct. 1999; 36 (4): 311-324. |
Dines et al.; Analysis of electrical conductivity imaging; Geophysics; Jul. 1981; 46 (7): 1025-1036. |
Osterman et al.; Multifrequency electrical impedance imaging: preliminary in vivo experience in breast; Physiological Measurement; Feb. 2000; 21 (1): 99-109. |
Ward et al.; Determination of Cole parameters in multiple frequency bioelectrical impedance analysis using only the measurement of impedances; Four-frequency fitting; Physiological Measurement; Sep. 2006; 27 (9): 839-850. |
Bernstein; A new stroke volume equation for thoracic electrical bio impedance; Critical Care Medicine; 1986; vol. 14; pp. 904-909. |
McAdams et al.; Tissue Impedance: a historical overview; Physiological Measurement, Institute of Physics Publishing, Bristol, GB; 16 (3A); pp. A1-A13; Aug. 1, 1995. |
Forslund et al., Evaluation of modified multicompartment models to calculate body composition in healthy males, Am. J. of Clin. Nutrition, 1996; 63:856-62. |
Van Loan et al., Use of bioelectrical impedance spectroscopy (BIS) to measure fluid changes during pregnancy, J. Appl. Physiol., 1995; 78:1037-42. |
De Lorenzo et al., Predicting body cell mass with bioimpedance by using theoretical methods: a technological review, J. Appl. Physiol., 1997; 82(5):1542-58. |
Zhu et al., Segment-specific resistivity improves body fluid volume estimates from bioimpedance spectroscopy in hemodialysis patients, J. Appl. Physiol., Oct. 27, 2005; 100:717-24. |
Thomas et al., Bioimpedance Spectrometry in the Determination of Body Water Compartments: Accuracy and Clinical Significance, Applied Radiation and Isotopes, 1998; 49(5/6):447-455, Elsevier Science Ltd., Oxford, GB. |
Cornish et al., Data analysis in multiple-frequency bioelectrical impedance analysis, Physiological Measurement, 1998; 19(2):275-283, Institute of Physics Publishing, Bristol, GB. |
Ulgen et al., Electrical Parameters of Human Blood, Proc. of the 20th Annual Int'l Conference of the IEEE Engineering in Medicine and Biology Soc., 1998; 20(6):2983-2986, IEEE Piscataway, NJ. |
Bracco et al., Bedside determination of fluid accumulation after cardiac surgery usign segmental bioelectrical impedance, 1998, Critical Care Medicine, vol. 26 No. 6, pp. 1065-1070. |
Chiolero et al., Assessmetn of changes in body water by bioimpedance in acutely ill surgical patients, 1992, Intensive Care Medicine, vol. 18, pp. 322-326. |
Chumlea et al., Bioelectrical impedance and body composition: present status and future directions, 1994 Nutrition Reviews, vol. 52, No. 4, pp. 123-131. |
Cornish et al., Bioelectrical impedance for monitoring the efficacy of lymphoedema treatment programmes, 1996, Breast Cancer Research and Treatment, vol. 38, pp. 169-176. |
Cornish et al., Quantification of lymphoedema using multi-frequency bioimpedance, 1998, Applied Radiation and Isotopes, vol. 49 No. 5/6, pp. 651-652. |
De Luca et al., Use of low-frequency electrical impedance mesurements to determine phospholipid content in amniotic fluid, 1996, Physics in Medicine and Biology, vol. 41, pp. 1863-1869. |
Derwent Abstract No. 97-474414, JP 09 220209 A (Sekisui Chem Ind Co Ltd) Aug. 26, 1997, see abstract. |
Derwent Abstract No. 99-138541, JP 10 014898 A (Sekisui Chem Ind Co Ltd) Jan. 20, 1998, see abstract. |
Derwent Abstract No. 99-138542, JP 10 014899 A (Sekisui Chem Ind Co Ltd) Feb. 20, 1998, see abstract. |
Derwent Abstract No. 99-247542, JP 11 070090 A (Sekisui Chem Ind Co Ltd) Mar. 16, 1999, see abstract. |
Duerenberg et al., Multi-frequency bioelectrical impedance: a comparison between the Cole-Cole modelling and Hanai equations with the classical impedance index approach, 1996, Annals of Human Biology, vol. 23, No. 1, pp. 31-40. |
Kim et al., Bioelectrical impedance changes in regional extracellular fluid alterations, 1997, Electromyography and Clinical Neurophysiology, vol. 37, pp. 297-304. |
Rigaud et al., Biolectrical impedance techniques in medicine, 1996, Critical Reviews in Biomedical Engineering, vol. 24 (4-6), pp. 257-351. |
Steijaert et al., The use of multi-frequency impedance to determine total body water and extracellular water in obese and lean female individuals, 1997, International Journal of Obesity, vol. 21, pp. 930-934. |
Ward et al., Multi-frequency bioelectrical impedance augments the diagnosis and management of lymphoedema in post-mastectomy, 1992, European Journal of Clinical Investigation, vol. 22, pp. 751-754. |
Gerth et al., A Computer-based Bioelectrical Impedance Spectroscopic System for Noninvasive Assessment of Compartmental Fluid Redistribution, Third Annual IEEE Symposium on Computer-Based Medical Systems Track 6: Clinical Assessment and Risk Evaluation/Session 13, 1990; 446-453. |
Kanai et al., Electrical measurement of fluid distribution in legs and arms, Dept. of Electrical Engineering, Sophia University, 1987; Medical Progress through Technology 12: 159-170, Copyright Martinus Nijhoff Publishers, Boston, MA USA. |
Number | Date | Country | |
---|---|---|---|
20100087750 A1 | Apr 2010 | US |